double placebo is one of 3 therapeutic programs targeting Heart Failure Preserved Ejection Fraction. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
3 competitors in Heart Failure Preserved Ejection Fraction
GLP-1RA
Henggliflozin
double placebo
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details